Olympus has entered into an exclusive agreement with Alesi Surgical Limited to distribute the Ultravision surgical smoke control system in the U.S.

Surgical smoke is a gaseous byproduct of tissue treated with electrical surgical devices, which are used for cautery, cutting, and ablation, among other uses. If not properly managed, surgical smoke can be hazardous to the health of people working within the surgical suite.

Physicians and nurses recommend using a smoke management device to reduce the risk of potential exposure to aerosolized contaminants and two U.S. states have passed laws mandating that hospitals install local exhaust ventilation systems in procedure rooms to control smoke and reduce the risk of staff exposure, with other state legislation pending. Clinical research has shown that Ultravision improves visibility, prevents the release of surgical smoke into the operating room, reduces patient CO2 exposure and facilitates “low pressure” laparoscopic surgery.
“Healthcare professionals are rightly concerned about risks posed by bioaerosols, especially during the pandemic. However, we must find safe ways to continue performing surgical procedures using minimally invasive techniques because of the significant clinical benefits this type of surgery offers patients," said Dr. Ross “Rusty” Segan, chief medical officer for Olympus Corporation, in a statement. "With its unique and highly characterized mode of action, Ultravision offers an innovative means to control bioaerosols during laparoscopic surgery.”

Ultravision is FDA-cleared for use in laparoscopic and open surgery. Ultravision suppresses the aerosolization of surgical smoke and mist using the highly characterized process of electrostatic precipitation.

Business Affairs Homepage